Showing posts with label Radiosurgery. Show all posts
Showing posts with label Radiosurgery. Show all posts

Saturday, September 29, 2012

Dr. Redmond, Johns Hopkins Pituitary Day

MEETING NOTES : Dr. Redmond, Johns Hopkins Pituitary Day


Meeting Created: September 29, 2012, 12:07 PM
Baltimore

radiotherapy indications
  • recurrence
  • persistent hormone secretion
  • inoperable
tumors repair more slowly than normal cells


IMRT (Intensity modulated radiation therapy)


stereotactic radiosurgery

  • more radiation beams, greater precision
  • very small tumors 1-5 treatments
  • larger 5-6 weeks
  • 150-300 radiation beams target area
  • Synergy machine
  • for divided course of radiation

cyberknife for 1-5 treatments


  • short-term 
  • fatigue
  • hair loss
  • tearful or dry eye
  • headache
  • nausea
  • long-term
  • cataracts
  • decreased hormones
  • damage to vision (rare)
  • second tumor (rare)
  • tumor control 90%
  • hormone normalization 60%









Monday, July 23, 2012

Notes on the Magic Cushing's Conference


Here are links to all the posts in order, although some still need to be edited.  I posted these directly from the meeting hall with no rereads or rewrites.  If anyone has anything to add, edit or delete, please let me know!

  • Magic Conference: Understanding your Pituitary Gland in Health and Disease
Dr. Frohman will present an overview of the pituitary gland. He will cover general aspects of pituitary function and testing and also review the types of pituitary disease that occur, including pituitary tumors and Sheehan’s Syndrome. Many people ask and wonder if Growth Hormone Deficiency can be inherited. Dr. Frohman will also briefly address that concern.


  • Magic Conference: Testing and Diagnosis Process for Pituitary Disorders
Pituitary disorders can be difficult to diagnose in many cases. Dr. Salvatori will discuss the different testing and diagnostic procedures to determine the pituitary disorder. MAGIC receives many calls asking about diagnostic procedures. This segment will be helpful in understanding what procedures are used today to provide the best treatment available. 

  • Magic Conference: Managing Medications and Aftercare of Treatments
It is crucial to monitor your treatments and aftercare of treatments when living with a pituitary disorder. Dr. Salvatori will discuss the importance of these issues so you will be aware of how to manage your pituitary disorder. A simple diagnosis does not mean that medications may be altered or changed in the future. This segment will assist you with information on how to manage your future.

  • Magic Conference: Cushing’s Disease, Are We Closer to Medical Therapies?
A significant proportion of patients with Cushing's Disease are not cured by primary surgical treatment, the disease is prone to relapse and significantly damages quality of life. Adjuvant radiotherapy is an increasingly unattractive option for clinicians who wish to spare their patients hypopituitarism and other potential complications. Some pharmacological options are currently available but tend to have dose-limiting side effects. New agents recently approved or under investigation will be discussed and strategies to select the optimal drug or drug combination for individual patients reviewed.

  • The Trip So Far...
MaryO's personal experiences and thoughts

  • Cushing's Help Turned Twelve During the Conference!
Twelve  years ago I was talking with my dear friend Alice, who runs a wonderful menopause site, Power Surge, wondering why there weren't many support groups online (OR off!) for Cushing's and I wondered if I could start one myself.  We decided that I could.
This website (http://www.cushings-help.com) first went "live" July 21, 2000 and the message boards September 30, 2000. Hopefully, with this site, I’ve made  some helpful differences in someone else's life.

  • Magic Conference: Treating Cushing’s Disease with Surgery: Ways of Achieving a Cure
Dr. McCutcheon will discuss the ways of treating Cushing’s disease from the surgical perspective, including the different ways of getting to the pituitary, the chances of success, and the potential complications. In addition, special nuances and pitfalls ofsurgery in Cushing’s (as opposed to other types of pituitary tumor) will be addressed. 

  • Phil and the Zebra Undies
Dr. McCutcheon is a surprise participant in a gift to Phil.

  • Real Talk: Psychological Process of Illness, part 1
This Segment will be broken into two sections. Part I will be provide an open opportunity for participants to ask relevant questions around the emotional/mental issues in living with a chronic illness. Participants will be able to openly talk about depression, anxiety, trauma, and other processes that occur when living illness.

Due to confidentiality issues, most of this segment is not shared.

  • Real Talk: Psychological Process of Illness, part 2
Part II will focus on seeing ourselves as survivors of illness and the process of staying empowered through illness that impacts us in such a powerful way. Principles of empowerment and how one can turn adversity into opportunity will be discussed. This segment should create an environment that is non judgmental and motivating.

Due to confidentiality issues, most of this segment is not shared.

  • The Rest Of The Trip
Wind-up and heading home
Eventually, all these posts will be edited, cleaned up and typos corrected.;

Thursday, November 18, 2010

Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety

Object: To assess the effects of radiosurgery (RS) on the radiological and hormonal control and its toxicity in the treatment of pituitary adenomas.


Methods: Retrospective analysis of 42 patients out of the first 48 consecutive patients with pituitary adenomas treated with RS between 1999 and 2008 with a 6 months minimum follow-up. RS was delivered with Gamma Knife as a primary or adjuvant treatment.


There were 14 patients with non-secretory adenomas and, among functioning adenomas, 9 were prolactinomas, 9 were adrenocorticotropic hormone-secreting and 10 were growth hormone-secreting tumors. Hormonal control was defined as hormonal response (decline of more than 50% from the pre-RS levels) and hormonal normalization.


Radiological control was defined as stasis or shrinkage of the tumor. Hypopituitarism and visual deficit were the morbidity outcomes.


Hypopituitarism was defined as the initiation of any hormone replacement therapy and visual deficit as loss of visual acuity or visual field after RS.


Results: The median follow-up was 42 months (6 -109 months). The median dose was 12,5 Gy (9 - 15 Gy) and 20 Gy (12 - 28 Gy) for non-secretory and secretory adenomas, respectively.


Tumor growth was controlled in 98% (41 in 42) of the cases and tumor shrinkage ocurred in 10% (4 in 42) of the cases. The 3-year actuarial rate of hormonal control and normalization were 62,4% and 37,6%, respectively, and the 5-year actuarial rate were 81,2% and 55,4%, respectively.


The median latency period for hormonal control and normalization was, respectively, 15 and 18 months. On univariate analysis, there were no relationships between median dose or tumoral volume and hormonal control or normalization.


There were no patients with visual deficit and 1 patient had hypopituitarism after RS.


Conclusions: RS is an effective and safe therapeutic option in the management of selected patients with pituitary adenomas. The short latency of the radiation response, the highly acceptable radiological and hormonal control and absence of complications at this early follow-up are consistent with literature.


Author: Douglas CastroSoraya CecilioMiguel Canteras
Credits/Source: Radiation Oncology 2010, 5:109

From: http://7thspace.com/headlines/364042/radiosurgery_for_pituitary_adenomas_evaluation_of_its_efficacy_and_safety.html